GLO1 and diabetic neuropathy: Groener et al. proposed several potential reasons for this inconsistency, including the use of inadequate surrogate markers to measure Glo-1 activity in the earlier research, the potential influence of unknown genetic factors linked to GLO1 polymorphisms that could alter the prospect of diabetic neuropathy, and the complex nature of methylglyoxal detoxification mechanisms.